Q/C Technologies, Inc. (QCLS): Shareholders' Equity
$21.75M
As of 2025-12-31
$16.09M
As of 2026-06-30
+14.0%
3-year compound annual growth
+12.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.75M | +122.2% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $9.79M | -20.9% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $12.37M | -15.8% | 2025-04-11, Balance as of period end |
| 2022-12-31 | $14.70M | -37.9% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $23.65M | n/m | 2023-03-31, Balance as of period end |
| 2020-12-31 | -$5.26M | n/m | 2022-03-31, Balance as of period end |
| 2019-12-31 | $9.36M | +60.4% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $5.83M | -22.8% | 2020-03-25, Balance as of period end |
| 2017-12-31 | $7.55M | +123.0% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $3.39M | -48.7% | 2018-07-13, Balance as of period end |
| 2015-12-31 | $6.60M | -55.4% | 2017-04-11, Balance as of period end |
| 2014-12-31 | $14.81M | +259.2% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $4.12M | n/a | 2015-03-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Q/C Technologies, Inc. (QCLS) | 2025-12-31 | $21.75M | +122.2% |
| Achieve Life Sciences, Inc. (ACHV) | 2025-12-31 | $21.52M | +3.0% |
| Immucell Corp (ICCC) | 2025-12-31 | $27.06M | -1.7% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $30.16M | +75.4% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | -$31.46M | n/m |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $68.78M | -16.5% |
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | $6.97M | -27.0% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | -$34.25M | n/m |
| Biomerica Inc (BMRA) | 2026-05-31 | $2.63M | -35.9% |
Compare QCLS, ACHV, ICCC, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗